Lynx1 Capital Management LP - May 31, 2023 Form 4 Insider Report for TScan Therapeutics, Inc. (TCRX)

Role
10%+ Owner
Signature
Lynx1 Capital Management LP, By: Lynx1 Capital Management GP LLC, its general partner, By: /s/ Weston Nichols, Sole Member
Stock symbol
TCRX
Transactions as of
May 31, 2023
Transactions value $
-$63,953
Form type
4
Date filed
6/2/2023, 05:35 PM
Next filing
Apr 23, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TCRX Common stock, $0.0001 par value per share Common Stock Sale -$25.1K -10K -0.19% $2.51 5.24M May 31, 2023 See footnote F1
transaction TCRX Common Stock Sale -$37.8K -15K -0.29% $2.52 5.23M May 31, 2023 See footnote F1
transaction TCRX Common Stock Sale -$1K -400 -0.01% $2.51 5.22M May 31, 2023 See footnote F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of ection 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.